Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin

被引：29

作者：

Arhin, Francis F. ^{[1
]}

Sarmiento, Ingrid ^{[1
]}

Parr, Thomas R., Jr. ^{[1
]}

Moeck, Gregory ^{[1
]}

机构：

[1] Med Co, St Laurent, PQ, Canada

来源：

关键词：

glycopeptide non-susceptible; MICs; MBCs;

D O I：

10.1093/jac/dkp286

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：868 / 870

页数：3

共 6 条

[1]

[Anonymous], M100S18 CLSI S

[2] Heteroresistance: a concern of increasing clinical significance? [J].

Falagas, M. E. ;

Makris, G. C. ;

Dimopoulos, G. ;

Matthaiou, D. K. .

[3]

FRITSCHE TR, 2008, 48 INT C ANT AG CHEM, P96

Jones, R. N. .

McKay, Geoffrey A. ;

Beaulieu, Sylvain ;

Arhin, Francis F. ;

Belley, Adam ;

Sarmiento, Ingrid ;

Parr, Thomas, Jr. ;

Moeck, Gregory .

[6]

*NAT COMM LAB STAN, 1999, M26A NCCLS